Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center at Barcelona Clinical Hospital, shared a post on LinkedIn:
“The breakthrough in HER2+ breast cancer presented at ESMO25 is not this study mentioned in La Vanguardia but the result of Destiny-Breast-05 (DB05), with the same immunoconjugate drug, trastuzumab deruxtecan, which was presented yesterday at the Presidential session.
The DB05 has had a great Spanish participation, and SOLTI cancer research has played a very important role. DB05 will surely be the new indication for the drug when it is evaluated by regulatory agencies and funded by our health system.
The population where it will be applied is a much smaller % of HER2+ breast cancer than is mentioned.
There are pros and cons, as always. Dr. Sara Tolaney of Boston’s Dana-Farber discussed it very elegantly yesterday.
Overall, this is very good news for apparently localized HER2+ breast cancer.”
You Can Also Read:
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
